Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer

4 Oct 2012

Abstract excerpt

The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear. We investigated CIMP and MSI status in colorectal cancer patients treated with adjuvant FOLFOX. Stages II and III sporadic colorectal cancer patients who underwent curative resection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Screening and Detection
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23034738
DOI: 10.1002/ijc.27888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancerPMID 23034738Read ↗

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Semantic proximity Read ↗

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Semantic proximity Read ↗

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Semantic proximity Read ↗

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.Semantic proximity Read ↗

Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.Semantic proximity Read ↗

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.Semantic proximity Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.Semantic proximity Read ↗

Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal CancerSemantic proximity Read ↗

The role of the CpG island methylator phenotype on survival outcome in colon cancer.Semantic proximity Read ↗

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.Semantic proximity Read ↗

KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.